Characteristics of Human Immunodeficiency Virus–Positive Participants (n = 596)
| Characteristic . | No. (%) or Median (IQR) . |
|---|---|
| Years since HIV diagnosis | 12.0 (6.6–17.1) |
| CD4 cell count, cells/µL | |
| Nadir CD4 count | 170 (70–260) |
| Mean CD4 in 12 mo prior to enrollment | 565 (432–740) |
| Cumulative duration of CD4 count < 200/µL, y | 0.9 (0.0–10.5) |
| CD4/CD8 ratio at enrollment | 0.7 (0.5–1.0) |
| History of CDC class C AIDS-defining diagnosis | 192 (32.2) |
| Using cART at enrollment | 571 (95.8) |
| Cumulative exposure to ART, y | 10.3 (4.5–14.5) |
| ART experienced before starting cART | 120 (21.0) |
| Having used zalcitabine | 169 (28.4) |
| Duration of zalcitabine usea, y | 2.7 (0.9–6.9) |
| HIV RNA < 200 copies/mL in year prior to enrollmentb | 542 (95.1) |
| Cumulative duration of HIV RNA < 200 copies/mLb, y | 8.7 (3.9–12.6) |
| Characteristic . | No. (%) or Median (IQR) . |
|---|---|
| Years since HIV diagnosis | 12.0 (6.6–17.1) |
| CD4 cell count, cells/µL | |
| Nadir CD4 count | 170 (70–260) |
| Mean CD4 in 12 mo prior to enrollment | 565 (432–740) |
| Cumulative duration of CD4 count < 200/µL, y | 0.9 (0.0–10.5) |
| CD4/CD8 ratio at enrollment | 0.7 (0.5–1.0) |
| History of CDC class C AIDS-defining diagnosis | 192 (32.2) |
| Using cART at enrollment | 571 (95.8) |
| Cumulative exposure to ART, y | 10.3 (4.5–14.5) |
| ART experienced before starting cART | 120 (21.0) |
| Having used zalcitabine | 169 (28.4) |
| Duration of zalcitabine usea, y | 2.7 (0.9–6.9) |
| HIV RNA < 200 copies/mL in year prior to enrollmentb | 542 (95.1) |
| Cumulative duration of HIV RNA < 200 copies/mLb, y | 8.7 (3.9–12.6) |
Abbreviations: ART, antiretroviral therapy; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile range.
aFor those who had used zalcitabine.
bIf currently on cART.
Characteristics of Human Immunodeficiency Virus–Positive Participants (n = 596)
| Characteristic . | No. (%) or Median (IQR) . |
|---|---|
| Years since HIV diagnosis | 12.0 (6.6–17.1) |
| CD4 cell count, cells/µL | |
| Nadir CD4 count | 170 (70–260) |
| Mean CD4 in 12 mo prior to enrollment | 565 (432–740) |
| Cumulative duration of CD4 count < 200/µL, y | 0.9 (0.0–10.5) |
| CD4/CD8 ratio at enrollment | 0.7 (0.5–1.0) |
| History of CDC class C AIDS-defining diagnosis | 192 (32.2) |
| Using cART at enrollment | 571 (95.8) |
| Cumulative exposure to ART, y | 10.3 (4.5–14.5) |
| ART experienced before starting cART | 120 (21.0) |
| Having used zalcitabine | 169 (28.4) |
| Duration of zalcitabine usea, y | 2.7 (0.9–6.9) |
| HIV RNA < 200 copies/mL in year prior to enrollmentb | 542 (95.1) |
| Cumulative duration of HIV RNA < 200 copies/mLb, y | 8.7 (3.9–12.6) |
| Characteristic . | No. (%) or Median (IQR) . |
|---|---|
| Years since HIV diagnosis | 12.0 (6.6–17.1) |
| CD4 cell count, cells/µL | |
| Nadir CD4 count | 170 (70–260) |
| Mean CD4 in 12 mo prior to enrollment | 565 (432–740) |
| Cumulative duration of CD4 count < 200/µL, y | 0.9 (0.0–10.5) |
| CD4/CD8 ratio at enrollment | 0.7 (0.5–1.0) |
| History of CDC class C AIDS-defining diagnosis | 192 (32.2) |
| Using cART at enrollment | 571 (95.8) |
| Cumulative exposure to ART, y | 10.3 (4.5–14.5) |
| ART experienced before starting cART | 120 (21.0) |
| Having used zalcitabine | 169 (28.4) |
| Duration of zalcitabine usea, y | 2.7 (0.9–6.9) |
| HIV RNA < 200 copies/mL in year prior to enrollmentb | 542 (95.1) |
| Cumulative duration of HIV RNA < 200 copies/mLb, y | 8.7 (3.9–12.6) |
Abbreviations: ART, antiretroviral therapy; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile range.
aFor those who had used zalcitabine.
bIf currently on cART.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
